Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CochlearCHEOF 60 3-Year ROIIC % is 13.49 as of Jun. 2025, which is 17% below its 10-year median of 16.30. GuruFocus rates CHEOF with a GF Score™ of 60/100 and a GF Value™ of $207.02 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Cochlear ranks better than 64.45% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Cochlear's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 13.49%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cochlear's 3-Year ROIIC % or its related term are showing as below:
CHEOF's 3-Year ROIIC % is ranked better than 64.45% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.615
vs CHEOF: 13.49
Cochlear (OTCPK:CHEOF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cochlear 3-Year ROIIC % Related Terms
Cochlear 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cochlear's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cochlear's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cochlear's 3-Year ROIIC % falls into.
Cochlear's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 198.291 (Jun. 2025) - 152.6494881 (Jun. 2022) )
/
( 1465.43 (Jun. 2025) - 1126.774 (Jun. 2022) )
=
45.6415119
/
338.656
=
13.48%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cochlear (CHEOF) has a 3-Year ROIIC % of 13.49 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cochlear and its competitors. This is 17% below median its historical median of 16.30. According to the industry distribution chart, Cochlear ranks #283 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 35.6%.
Is Cochlear's 3-Year ROIIC % too high?
Cochlear's current 3-Year ROIIC % of 13.49 is 17% below median its 10-year median of 16.30. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. Cochlear's value of 13.49 is 735.3% above this industry median. Based on the distribution chart, Cochlear ranks #283 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cochlear has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #283 out of 796 companies for 3-Year ROIIC %. This puts Cochlear in the upper half of its industry. The industry median 3-Year ROIIC % is 1.62. Cochlear's value of 13.49 is 735.3% above this benchmark. While the company's 10-year median is 16.30 vs. the industry median of 1.62, Cochlear has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current 3-Year ROIIC % of 13.49 is 735.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current 3-Year ROIIC % is 13.49, which is 17% below median its own 10-year median of 16.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOF) is currently considered Significantly Undervalued. The stock's GF Value™ is $207.02, compared to a current price of $81.92 — trading 60.4% below its estimated fair value. The current 3-Year ROIIC % is 13.49, which is 17% below median its 10-year median of 16.30 and 735.3% above the Medical Devices & Instruments industry median of 1.62. Cochlear's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Cochlear (CHEOF), the current 3-Year ROIIC % is 13.49 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (CHEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of $81.92 is trading 60.4% below its estimated GF Value™ of $207.02.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for CHEOF:
3-Year ROIIC %: 13.49 (17% below median its 10-year median of 16.30)
GF Value™: $207.02 vs. price of $81.92 (60.4% below fair value)
Industry Position: 735.3% above the Medical Devices & Instruments median (#283 of 796)
No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
60GF Score
Get the complete analysis for CHEOF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHEOF has been successfully added to your 
